<i>EGFR</i>+ NSCLC: Multidisciplinary Overview
Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease

Released: January 26, 2022

Expiration: January 25, 2023

Elise Hitron
Elise Hitron, MSN, FNP-C
Frank Schneider
Frank Schneider, MD

Activity

Progress
1
Course Completed

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include:

  • Testing for targetable biomarkers
  • Talking with patients about biomarker testing
  • Frontline therapy for EGFR-positive NSCLC
  • Resistance to front-line osimertinib
  • Treatment of EGFR TKI–resistant disease, including the emerging antibody–drug conjugate patritumab deruxtecan
  • HER3 protein testing
  • Pathology considerations
  • Nursing considerations
  • Interdisciplinary communication